FluoGuide A/S (Nasdaq: FLUO)

FluoGuide is a clinical-stage biotech company specializing in precision cancer surgery. Our mission is to improve outcomes for cancer patients by helping surgeons remove cancer more accurately. Our lead product, FG001, has been clinically proven to light up cancer during surgery, guiding more precise removal while preserving healthy tissue. FG001 has shown strong results in brain, head and neck, and lung cancers, and is well-tolerated by patients. Scientific data and clinical experience suggest its broad potential across solid tumor types. Strategic partnerships with surgical equipment manufacturers support integration and wide adoption of FG001 in the operating room. FluoGuide is listed on the Nasdaq First North Growth Market in Stockholm under the ticker symbol "FLUO." For more information about FluoGuide's pipeline, technology, and upcoming events, visit www.fluoguide.com.